Genprex – FDA Grants Fast Track Approval For Promising New Cancer Gene Therapy

Rodney Varner, CEO, Chairman & President of Genprex, Inc. GNPX, was recently a guest on Benzinga’s All-Access.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. 

The company has recently received a new FDA Fast Track approval for its lead candidate, Reqorsa.

Watch the full interview here:

Featured photo by Hal Gatewood on Unsplash.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.